Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-201 and HB-202 with Chemotherapy for HPV16+ Oropharyngeal Cancer
NCT05108870Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Aug 2022
- Primary completion
- Jan 2027
- Modality
- Oncolytic Viruses, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HB-201 and HB-202 in oropharyngeal squamous cell carcinoma (OPSCC) (4 arms), sponsored by University of Chicago. Primary endpoints: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy at 2 years and Deep Response Rate at 2 years. Started Aug 2022; status: active, not recruiting.
02
Drugs
HB-201HB-202
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05108870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108870.